British drugmaker GlaxoSmithKline (LSE: GSK) has said it will kick off late stage development of its novel immunological candidate otilimab.
The biologic is an investigational anti GM-CSF monoclonal antibody, which boasts encouraging Phase II results from the BAROQUE study, announced in October 2018.
GSK owns exclusive global rights to the therapy under the terms of a 2013 agreement with German biotech firm MorphoSys (FSE: MOR), worth a potential 445 million euros ($502 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze